ArticleJapanese journal of ophthalmology2025
Clinical study of thyroid eye disease combined with myasthenia gravis.
Article in Japanese journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the clinical features and prognostic factors of patients with thyroid eye disease (TED) combined with myasthenia gravis (MG) at a tertiary comprehensive hospital in China during a 10-year period. STUDY
designretrospective study.
methodsA case series of patients diagnosed with TED combined with MG was conducted at a tertiary general hospital over 10 years. Medical records of general conditions, clinical presentation, imaging and laboratory tests, treatment modalities, and prognostic outcomes were reviewed.
resultsTwenty-three patients with TED combined with MG were found throughout the study period. The mean age was 42.57 ± 14.89 years with 10 men and 13 women. Ocular motility disorders (82.61%), diplopia (73.91%), and ptosis (73.91%) were the primary clinical manifestations, and ocular motility disorders with limited movement in all directions were common (17 eyes) (50.00%). Active (69.57%) and moderate-to-severe (82.61%) TED was common, and hyperthyroidism was the most common complication of thyroid disease (57.17%). Ocular MG was the predominant subtype of MG (86.96%). Chest CT or pathologic examination identified thymic hyperplasia in 4 patients (17.39%) and thymoma in 1 patient (4.35%). A statistically significant association was observed between smoking and an unfavorable prognosis of TED combined with MG (P<0.05).
conclusionsMG should be taken into account in patients with TED who exhibit the following: unilateral or bilateral ptosis, ptosis in one eye and upper eyelid retraction in the other, obvious eye movement disorders without or with mild involvement of the extraocular muscles on imaging, and symptoms of morning and evening fluctuations. Ophthalmologists should refer these patients to the Department of Neurology to avoid misdiagnosis or underdiagnosis. The co-occurrence of TED and MG is rare clinically, mostly affecting young and middle-aged women, with ocular MG and hyperthyroidism as the main clinical subtype, and thymic hyperplasia or thymoma in a small percentage. Smoking is an independent risk factor for poor prognosis of TED combined with MG.
Indexed as
Identifiers
40323520What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.